WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

Denny Bros will be attending London Packaging Week 2025 on the 15th and 16th of October, and their booth number is C84.

Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Arvinas, in collaboration with Pfizer, has announced vepdegestrant NDA acceptance by the FDA for breast cancer treatment.

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

MAXONA Pharmaceuticals has submitted an IND application seeking approval from the US FDA for its lead compound, MAX-001, to treat acute pain.